Pamitum Injection (Panitumumab): Precision EGFR Inhibition for mCRC – Global Supply by Ernest Oncology
In the rapidly advancing oncology sector of 2026, Pamitum (Panitumumab) stands as a vital therapeutic option for adult patients with wild-type RAS metastatic colorectal cancer (mCRC).
Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure international distribution of Pamitum to the USA, UK, London, Abu Dhabi, Australia, and South Africa, providing validated cold-chain logistics and complete regulatory documentation.
Technical Product Profile: Pamitum (Panitumumab) 100mg/5mL
Pamitum is formulated as a sterile, preservative-free solution for intravenous (IV) infusion.
Product Specifications
Active Ingredient: Panitumumab.
Concentration: 20 mg/mL (Standard 100 mg/5 mL single-dose vial).
Mechanism of Action: EGFR Antagonist; binds to the extracellular domain of EGFR to inhibit ligand-induced tyrosine kinase phosphorylation.
Therapeutic Class: Targeted Biologic / Monoclonal Antibody.
Storage Requirements: Must be maintained in a specialized cold chain at 2°C to 8°C (36°F to 46°F).
Do not freeze or shake. Protect from direct sunlight.
Primary Clinical Indications
Metastatic Colorectal Cancer (mCRC): Indicated as a first-line treatment in combination with FOLFOX or as monotherapy following disease progression in patients with confirmed wild-type RAS (KRAS and NRAS) status.
Biomarker Necessity: Use is strictly indicated for patients whose tumors do not harbor mutations in exons 2, 3, and 4 of KRAS and NRAS.
Why Source Pamitum via Ernest Oncology?
Fully Human Antibody Precision: The IgG2 structure offers a favorable safety profile, minimizing immunogenicity and improving patient tolerance during long-term treatment cycles.
Proven Therapeutic Efficacy: Significant improvements in progression-free survival (PFS) when utilized in modern oncology regimens.
Validated Cold-Chain Excellence: Ernest Oncology employs IATA-certified, temperature-monitored packaging to ensure Pamitum maintains its biologic potency from India to London, Abu Dhabi, or Sydney.
Global Compliance: Every shipment includes a Certificate of Analysis (CoA) and adheres to international Good Distribution Practices (GDP), ensuring seamless customs clearance in highly regulated markets.
Global Distribution Reach: USA, UK, UAE, Australia, & South Africa
We specialize in high-efficiency pharmaceutical exports to major international healthcare hubs:
USA: Reliable procurement for specialized cancer centers and B2B pharmaceutical wholesalers.
UK & London: Supporting NHS Trusts and private oncology networks with consistent supply of critical biologics.
Abu Dhabi (UAE): Rapid delivery to the advanced clinical infrastructure and hospitals of the Middle East.
Australia: Navigating TGA-compliant pathways to supply Australian oncology departments with authentic medications.
South Africa: Expanding access to high-tier targeted therapies across the Southern African medical sector.
📞 Contact Ernest Oncology — Pharmaceutical Exporter from India
(Group of Ernest Pharmaceutical Pvt. Ltd.)
Partner with a verified leader for the bulk procurement of Pamitum and specialized oncology medications.
🌐 Websites:
📧 Email:
📦 Business Type: Exporter | Bulk Supplier | Distributor
📲 WhatsApp: +91 93599 02383
🔗 Instant Chat:
